Beovu (brolucizumab-dbll) / Novartis - LARVOL DELTA

Functional and anatomic outcomes of brolucizumab in adults with neovascular age-related macular degeneration - The OCTOPUS cohort study. (PubMed, J Fr Ophtalmol) - "CNV lesion size as assessed by OCTA decreased with brolucizumab, which also led to vision gains and better anatomic outcomes."

Clinical • Journal • Age-related Macular Degeneration • Inflammation • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Sterile Intraocular Inflammation Following Intravitreal Injections: Pathogenesis, Clinical Features, and Management. (PubMed, Int Ophthalmol Clin) - "Epidemiologic data show variable incidence across agents, with brolucizumab demonstrating higher rates of inflammation compared with ranibizumab or aflibercept. Treatment includes corticosteroids and discontinuation of the offending agent, with rare cases requiring surgical intervention. As the therapeutic landscape expands, heightened awareness and standardized evaluation of postinjection inflammation are critical to improving safety and preserving vision."

Journal • Review • Age-related Macular Degeneration • Inflammation • Macular Degeneration • Ocular Infections • Ocular Inflammation • Ophthalmology • Retinal Disorders • Uveitis • Vasculitis

Effectiveness and Safety of Intravitreal Brolucizumab for Diabetic Macular Edema After Vitrectomy: A Before-and-After Study at a Specialized Center in Japan. (PubMed, Clin Ophthalmol) - "If CST did not improve after the last IVBr injection, treatment was switched to intravitreal triamcinolone acetonide injection (IVTA), sub-Tenon's triamcinolone acetonide (STTA) injection, or intravitreal faricimab (IVFa)...Our findings demonstrated partial efficacy of IVBr in managing DME in vitrectomized eyes. However, variable responses often necessitate supplementary treatments to achieve therapeutic goals."

Journal • Diabetes • Diabetic Macular Edema • Inflammation • Metabolic Disorders • Ophthalmology

Comparison of ocular blood flow changes at 30 minutes after intravitreal injection of faricimab, brolucizumab, and aflibercept 2 mg for neovascular age-related macular degeneration. (PubMed, Retina) - "Ocular blood flow significantly decreased 30 minutes post-injection in faricimab-, brolucizumab-, or aflibercept-treated eyes with nAMD. Brolucizumab-treated eyes showed a significantly greater reduction in choroidal blood flow than aflibercept-treated eyes."

Journal • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Disease control, visual and anatomic outcomes at week 48 of brolucizumab treatment in patients with previously suboptimal anatomically controlled neovascular age-related macular degeneration - The SWIFT study. (PubMed, J Fr Ophtalmol) - P3 | "In patients with refractory nAMD, brolucizumab allowed control of disease activity for up to 41.0% of patients, with visuals gains, anatomical improvements and extended treatment interval, despite poor response and discontinuation for some patients in addition to a 9.8% rate of IOI."

Journal • Age-related Macular Degeneration • Inflammation • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Efficacy and Safety of Brolucizumab in Neovascular Age‑related Macular Degeneration – A Real-world Study (SOE 2025) - "In this real-world study, brolucizumab demonstrated its effectiveness in maintaining CDVA while significantly improving key anatomical parameters, consistent with the HAWK and HARRIER trials. These findings support the use of brolucizumab in clinical practice, but highlight the need for careful patient selection and close monitoring for adverse events."

Clinical • Real-world • Real-world evidence • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Real-world outcomes, including intraocular inflammation, after intravitreal brolucizumab for diabetic macular edema. (PubMed, Jpn J Ophthalmol) - "IOI developed in four of 56 (7.1%) eyes and responded well to prompt steroid therapy after 1.5 years of IVBr use for DME. BCVA and CMT improved at all evaluation time points. With an average of 3.8 IVBr injections per year, IVBr showed long-term efficacy for DME in the real-world setting, although the occurrence of IOI should be monitored."

Journal • Real-world evidence • Diabetic Macular Edema • Inflammation • Ocular Inflammation • Ophthalmology

Usage of brolucizumab as treatment for wet age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV): A narrative review. (PubMed, Medicine (Baltimore)) - "Brolucizumab is one of the latest anti-VEGF agents clinically proven to treat nAMD after on-label agents namely, ranibizumab and aflibercept. However, it also has a risk of intraocular inflammation. This review summarizes the evidence for brolucizumab in the treatment of nAMD."

Journal • Review • Age-related Macular Degeneration • Cardiovascular • Coronary Artery Disease • Macular Degeneration • Oncology • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Brolucizumab clinical and safety outcomes in a neovascular age-related macular degeneration national database: Fight Retinal Blindness Spain (FRB Spain). (PubMed, Eye (Lond)) - "In this series BRO achieves an extension in the treatment intervals in half of the patients which require frequent reinjections (<8 weekly), reducing MNV activity in a third of this specific difficult-to-treat subgroup. The adverse event rates described are consistent with other cohorts and need to be considered to inform treatment decisions in case-by-case discussions."

Journal • Age-related Macular Degeneration • Macular Degeneration • Ocular Inflammation • Ophthalmology • Retinal Disorders • Uveitis • Vasculitis • Wet Age-related Macular Degeneration

TALON Phase IIIb Study: 32 Week Primary Results of Brolucizumab Using Treat and Extend for Neovascular Age Related Macular Degeneration. (PubMed, Ophthalmol Retina) - "In TALON, more brolucizumab-treated patients achieved longer treatment interval without DA than aflibercept with comparable visual gains. Brolucizumab showed improved anatomical outcomes and demonstrated an overall favorable benefit/risk profile."

Journal • P3 data • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

BEST: Brolucizumab Efficacy and Safety Single-Arm Descriptive Trial in Patients With Persistent Diabetic Macular Edema (clinicaltrials.gov) - P4 | N=52 | Active, not recruiting | Sponsor: Guangdong Provincial People's Hospital | Recruiting ➔ Active, not recruiting

Enrollment closed • Diabetic Macular Edema • Ophthalmology

Association between intravitreal anti-vascular endothelial growth factor agents and hypertension: a meta-analysis. (PubMed, Can J Ophthalmol) - "This meta-analysis found no significant difference in hypertension risk between different intravitreal anti-VEGF agents or sham injection. These results reinforce the notion that these agents have similar and safe side effect profiles, and that the choice of agent should not be based on the risk of hypertension."

Clinical • Journal • Retrospective data • Cardiovascular • Hypertension

Authors' response: "Brolucizumab-associated intraocular inflammation in Indian patients by VRSI study group". (PubMed, Indian J Ophthalmol) - No abstract available

Journal • Inflammation • Ocular Inflammation

Brolucizumab results and adverse visual outcomes study: A single-center real-world Indian experience. (PubMed, Indian J Ophthalmol) - No abstract available

Adverse events • Journal • Real-world evidence

Comment on "Brolucizumab-associated intraocular inflammation in Indian patients by VRSI study group". (PubMed, Indian J Ophthalmol) - No abstract available

Journal • Inflammation • Ocular Inflammation

Real-World Outcomes of Brolucizumab Treatment in Japanese Patients with Neovascular Age-Related Macular Degeneration: A 12-Month, Multicenter Study. (PubMed, Ophthalmol Ther) - P | "In a real-world clinical setting, brolucizumab was effective at drying the retina in treatment-naïve and pre-treated Japanese nAMD patients and therefore has the potential to reduce the treatment burden by prolonging injection intervals. Safety outcomes support the overall favorable benefit/risk profile of brolucizumab."

Clinical • Journal • Real-world evidence • Age-related Macular Degeneration • Inflammation • Macular Degeneration • Ocular Inflammation • Ophthalmology • Retinal Disorders • Vasculitis • Wet Age-related Macular Degeneration

Successful Response to Intravitreal Faricimab Injections in a Case of Neovascular Age-Related Macular Degeneration in Vitrectomized Eyes. (PubMed, Cureus) - "We report a case of nAMD in a vitrectomized eye that showed inadequate response to both aflibercept and brolucizumab, but experienced effective suppression of exudation following intravitreal administration of faricimab. This case suggests that faricimab may offer a therapeutic benefit in managing exudative changes in vitrectomized eyes with nAMD."

Journal • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

The effect of brolucizumab on diabetic macular edema and ischemia; a real-world analysis. (PubMed, Eur J Ophthalmol) - "Choriocapillaris flow deficit (CCFD%) also improved after the loading dose (40.3 vs. 35.3, p = 0.03). Although not statistically significant, there was also an improved foveal circularity.ConclusionIntravitreal brolucizumab leads to significant functional and anatomical improvement in diabetic macular edema and has also a beneficial effect on macular ischemia as shown by improvement in both retinal and choroidal perfusion."

Journal • Real-world evidence • Cardiovascular • Diabetic Macular Edema • Ophthalmology

Drug-induced Vasculitis and Choroiditis after Brolucizumab. (PubMed, Ophthalmol Retina) - "This study reports two cases of drug-induced immune-mediated retinal vasculopathy and choroiditis following intravitreal brolucizumab, highlighting its clinical features, severity, and irreversibility, emphasizing vigilant monitoring and multidisciplinary management to prevent vision-threatening complications."

Journal • Genetic Disorders • Inflammation • Ocular Inflammation • Ophthalmology • Retinal Disorders • Vasculitis

Real-world safety and efficacy of Anti-VEGF treatment in Brazil. (PubMed, Arq Bras Oftalmol) - "This real-world study, the largest of its kind in Brazil, confirms the safety and efficacy of antiangiogenic therapies in the southern Brazilian private healthcare system. The findings highlight a low incidence of severe adverse events and outcomes consistent with global studies, supporting the ongoing use of antiangiogenic agents as effective and well-tolerated treatments for various ocular conditions in developing countries."

Journal • Real-world evidence • Retrospective data • Age-related Macular Degeneration • Diabetic Macular Edema • Diabetic Retinopathy • Macular Degeneration • Ocular Infections • Ocular Inflammation • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion • Wet Age-related Macular Degeneration

Clinical implication of aberrant choroidal feeding artery in type 1 macular neovasculopathy. (PubMed, Sci Rep) - "Patients with aberrant choroidal feeding arteries achieved a dry macula of a similar percentage (P = 0.680) with more frequent anti-vascular endothelial growth factor injections (P = 0.005) and a switch to brolucizumab (P = 0.042) during a similar follow-up period (P = 0.305). Type 1 MNV with aberrant choroidal feeding arteries showed distinct characteristics from unimpeded blood flow (Large PED and sub-RPE deposits), suggesting that the aberrant choroidal arteries serve not only as a source of blood flow but also contribute to the development of MNV by arteriogenesis."

Journal • Age-related Macular Degeneration

Intraocular Inflammation, Safety Events, and Outcomes After Intravitreal Injection of Ranibizumab, Aflibercept, Brolucizumab, Abicipar Pegol, and Faricimab for nAMD. (PubMed, J Vitreoretin Dis) - " Abicipar pegol and brolucizumab were associated with a higher incidence of ocular AEs in phase 3 randomized controlled trials. The potential benefits of these drugs should be weighed against the AEs."

Clinical • Journal • Review • Age-related Macular Degeneration • Diabetic Retinopathy • Inflammation • Macular Degeneration • Ocular Infections • Ocular Inflammation • Ophthalmology • Retinal Disorders • Uveitis • Vasculitis • Wet Age-related Macular Degeneration

Proactive Post-Injection Monitoring in Brolucizumab Therapy: A Study on Intraocular Inflammation and Treatment Outcomes. (PubMed, Clin Ophthalmol) - "This study highlights the incidence of IOI with Brolucizumab in a real-world setting, emphasizing the importance of proactive monitoring and early intervention. Despite the occurrence of inflammation, visual outcomes were generally favorable, supporting the safety of Brolucizumab when managed carefully."

Journal • Age-related Macular Degeneration • Inflammation • Macular Degeneration • Ocular Inflammation • Ophthalmology • Pain • Retinal Disorders • Vasculitis • Wet Age-related Macular Degeneration

Comparison of one-year outcomes between aflibercept and brolucizumab for treatment-naïve pachychoroid neovasculopathy. (PubMed, Sci Rep) - "These findings suggested that as-needed administration of brolucizumab demonstrated comparable visual outcomes to aflibercept in treatment-naïve PNV eyes. Additionally, over 12 months, brolucizumab showed a greater effect in reducing CMT, SFCT, and Haller layer thickness, as well as increasing CVI, suggesting potential choroidal morphology remodeling."

Clinical • Journal • Retrospective data • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Comparative efficacy of intravitreal anti-VEGF therapy for neovascular age-related macular degeneration: A systematic review with network meta-analysis. (PubMed, Acta Ophthalmol) - "The reference for comparison was monthly ranibizumab...For CRT, small but statistically significant improvements over the reference were observed for brolucizumab 3 mg (-27.9 μm) or 6 mg (-38.1 μm) in loading dose (LD) then every 8-12 weeks, aflibercept 8 mg in LD then every 12 (-26.9 μm) or 16 weeks (-32.1 μm), faricimab 6 mg in LD then treat-and-extend (-18.1 μm) and aflibercept 2 mg in LD then every 8 weeks (-11.3 μm)...When results are considered simultaneously, faricimab 6.0 mg or aflibercept 8.0 mg in a treatment regimen with an LD followed by either a treat-and-extend regimen or a fixed 12- or 16-week regimen appears to provide the optimal balance between visual outcomes, anatomical outcomes and the lowest treatment burden. However, studies of the long-term efficacy of newer anti-VEGF drugs are warranted."

Journal • Retrospective data • Review • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration